Leiby J M
Department of Medicine, Hematology/Oncology, Ohio State University Hospitals, Columbus 43210.
Semin Oncol. 1988 Apr;15(2 Suppl 2):27-31.
Trimetrexate, a nonclassical antifolate, was administered to 28 patients with progressive, metastatic breast cancer. The starting dose was 8 mg/m2 administered intravenously (IV) as a short infusion daily for 5 days, repeated every 3 weeks with dose adjustments depending on patient tolerance. The median age of the 28 females in this study was 58.5 years. Their median performance status on the Zubrod scale was 1. Nine of the patients were estrogen-receptor positive. The sites of metastasis included the pulmonary system (50%), bone (40%), and liver (35%). Twenty patients were evaluable for response. Three patients (15%; [95% confidence interval 0.0, 30.6]) achieved a partial response with a median time to partial response of 9.1 weeks and a median duration of partial response of 13.1 weeks. Two of the responders were estrogen-receptor positive. Median survival for all 28 patients was 41 + weeks with 15 patients alive at the last follow-up. Hematologic grade 3-4 toxicity occurred as follows: leukopenia (21%), thrombocytopenia (18%), and granulocytopenia (18%). There was no significant nonhematologic toxicity seen.
三甲曲沙，一种非经典抗叶酸药物，被用于治疗28例进展期转移性乳腺癌患者。起始剂量为8mg/m²，通过静脉短时间输注给药，每日1次，共5天，每3周重复一次，并根据患者耐受性调整剂量。本研究中28名女性的中位年龄为58.5岁。她们在Zubrod量表上的中位体能状态为1级。9名患者雌激素受体呈阳性。转移部位包括肺部系统（50%）、骨骼（40%）和肝脏（35%）。20名患者可评估疗效。3名患者（15%；[95%置信区间0.0, 30.6]）获得部分缓解，部分缓解的中位时间为9.1周，部分缓解的中位持续时间为13.1周。两名缓解者雌激素受体呈阳性。所有28名患者的中位生存期为41周以上，最后一次随访时有15名患者存活。血液学3 - 4级毒性发生率如下：白细胞减少（21%）、血小板减少（18%）和粒细胞减少（18%）。未观察到明显的非血液学毒性。
